Skip to main content

Annalisa Jenkins

PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.